Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
|Videos|June 12, 2021
Looking to the future of cataract surgery
Author(s)Ashley Behrens, MD
In recognition of Cataract Awareness Month.
Advertisement
Ashley Behrens, MD, chief, Division of Comprehensive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, offers a look at the current technology available for IOL implantation, as well as what's in the pipeline for cataract surgery advancements.
Advertisement
Related to this article
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Duravyu misses wet AMD end point again as EyePoint pivots to DME
3
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
4
CHMP recommends ranibizumab biosimilar Fovlussea for retinal disease
5